Dihexa 30 Tablets 8mg

Description

Strength: 8mg
CAS: 1401708-83-5
Chemical Formula: C₂₇H₄₄N₄O₅
Molecular weight: 504.66 g/mol
Peptide Sequence: Hexanoyl-Tyr-Ile-Unk (N-Hexanoyl-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide
Synonyms: PNB-0408, fosgonimeto
Storage: Store in a cool, dry place at controlled room temperature. Protect from light and moisture.
Shelf life: 24 months from the manufacturing date.

Dihexa (8 mg) is a synthetic peptide-like compound derived from angiotensin IV–related research. Dihexa has been investigated in laboratory studies exploring neurobiological processes, including synaptic activity and cognitive function models. Research has focused on its potential interaction with hepatocyte growth factor (HGF)/c-Met signaling systems involved in neural signaling.

• Peptide sequence: N-Hexanoyl-L-tyrosyl-N-(6-amino-6-oxohexyl)-L-isoleucinamide
• Molecular formula: C₂₇H₄₄N₄O₅
• Molecular weight: 504.66 g/mol
• CAS number: 1401708-83-5
• Studied in neurobiology and cognitive research models
• Stable for up to 24 months when properly stored
• For laboratory research use only

Dihexa is being researched for its potential role in central nervous system studies. Preclinical investigations have examined its activity in models related to:

• Synaptic function research
• Neuroplasticity investigations
• Synaptogenesis and dendritic spine density studies
• Memory and learning models
• HGF/c-Met signaling systems

In experimental settings, Dihexa has been studied for its interaction with hepatocyte growth factor (HGF)/c-Met signaling systems. Research suggests it may influence pathways associated with neuronal connectivity in laboratory models.

Research remains preclinical and investigational.

Published preclinical research has evaluated Dihexa primarily in animal and in vitro models. Reported experimental dosing has included:

• Low milligram per kilogram (mg/kg) dosing ranges in animal studies
• Oral and parenteral administration routes in research settings
• Variable duration protocols depending on study design

Observed research findings have included changes in synaptic markers and performance in laboratory-based behavioral models. These findings are limited to experimental research and are not clinical recommendations. No approved therapeutic dosing guidelines exist.

• Store at –20 °C for long-term preservation; 2–8 °C for short-term handling. Protect from light and moisture.
• Protect from light and moisture
• Avoid repeated exposure to humidity
• Handle using appropriate laboratory protective equipment
• Dispose of materials in accordance with institutional chemical safety and biosafety guidelines

References

1. Wright JW, Harding JW. The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease. J Alzheimers Dis. 2015;45(4):985-1000. doi:10.3233/JAD-142814
2. Desole C, Gallo S, Vitacolonna A, et al. HGF and MET: From Brain Development to Neurological Disorders. Front Cell Dev Biol. 2021;9:683609. Published 2021 Jun 9. doi:10.3389/fcell.2021.683609
3. Ho JK, Nation DA. Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. 2018;92:209-225. doi:10.1016/j.neubiorev.2018.05.005
4. Johnston JL, Reda SM, Setti SE, et al. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023;20(2):431-451. doi:10.1007/s13311-022-01325-5
5. National Center for Biotechnology Information. PubChem Compound Summary for CID 125355097, Dihexa (PNB-0408). https://pubchem.ncbi.nlm.nih.gov/compound/Dihexa-_PNB-0408

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.